Valentina Rossi Selected Research

Therapeutics

8/2021	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
10/2019	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
10/2018	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
1/2018	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
2/2016	AKT signaling in ERBB2-amplified breast cancer.
1/2016	Prostate cancer stem cells: the role of androgen and estrogen receptors.
8/2015	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
2/2014	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
2/2014	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
10/2012	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Valentina Rossi Research Topics

Disease

22	Neoplasms (Cancer) 05/2021 - 07/2002
19	Breast Neoplasms (Breast Cancer) 08/2021 - 01/2010
4	Inflammation (Inflammations) 05/2022 - 06/2014
3	Prostatic Neoplasms (Prostate Cancer) 01/2016 - 09/2006
2	Lactic Acidosis 08/2022 - 01/2022
2	Multiple Sclerosis 05/2022 - 01/2020
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 07/2002
2	Neoplasm Metastasis (Metastasis) 08/2021 - 05/2021
2	Dysbiosis 07/2021 - 01/2020
2	Residual Neoplasm 01/2018 - 07/2002
2	Gastroesophageal Reflux (GERD) 03/2016 - 12/2009
2	Ischemic Stroke 06/2014 - 07/2011
2	Postoperative Pain 07/2011 - 06/2009
2	Squamous Cell Carcinoma of Head and Neck 01/2010 - 07/2007
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2010 - 07/2007
2	Infections 09/2003 - 07/2002
1	Fatigue 08/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2022
1	Liver Neoplasms (Liver Cancer) 01/2022
1	Femoral Fractures (Femoral Fracture) 01/2022
1	Neutropenia 12/2021
1	Hallux Valgus 11/2021
1	Pain (Aches) 10/2021
1	Melanoma (Melanoma, Malignant) 05/2021
1	Peripheral Nervous System Diseases (PNS Diseases) 02/2020
1	Hirschsprung Disease (Hirschsprung's Disease) 01/2019
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2018
1	Anemia 04/2018
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Mood Disorders (Mood Disorder) 01/2016
1	Celiac Disease (Celiac Sprue) 01/2015

Drug/Important Bio-Agent (IBA)

11	Trastuzumab (Herceptin)FDA Link 10/2018 - 01/2010
8	EnzymesIBA 08/2022 - 11/2006
6	Proteins (Proteins, Gene)FDA Link 01/2016 - 09/2006
5	Hormones (Hormone)IBA 05/2022 - 01/2012
5	Biological ProductsIBA 10/2021 - 03/2011
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2012
4	Nicotinamide N-MethyltransferaseIBA 04/2013 - 11/2006
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 08/2022 - 01/2021
3	Lactic Acid (Lactate)FDA LinkGeneric 08/2022 - 01/2021
3	ErbB Receptors (EGF Receptor)IBA 10/2018 - 01/2010
3	Lapatinib (GW572016)FDA Link 10/2018 - 02/2014
3	N-nitroso-N-methyltyramine (NNMT)IBA 04/2013 - 07/2007
3	XenobioticsIBA 01/2010 - 11/2006
2	Pyruvic Acid (Pyruvate)IBA 08/2022 - 01/2022
2	CatecholaminesIBA 05/2022 - 06/2008
2	Lactate Dehydrogenase 5IBA 01/2022 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 11/2006
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 02/2015
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2021
2	Fatty Acid-Binding ProteinsIBA 01/2020 - 06/2014
2	Phosphotransferases (Kinase)IBA 10/2019 - 02/2016
2	Phenobarbital (Luminal)FDA Link 04/2016 - 11/2012
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016 - 03/2011
2	BilirubinIBA 06/2014 - 05/2011
2	Pharmaceutical PreparationsIBA 04/2013 - 11/2006
2	Monoclonal AntibodiesIBA 03/2011 - 07/2002
1	Oxygen (Dioxygen)IBA 08/2022
1	Lactate DehydrogenasesIBA 08/2022
1	Citric Acid (Citrate)FDA LinkGeneric 08/2022
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 05/2022
1	beta-Endorphin (Endorphin, beta)IBA 05/2022
1	Clopidogrel (Plavix)FDA Link 01/2022
1	ibrutinibIBA 12/2021
1	17- N,N- diethylcarbamoyl- 4- methyl- 4- azaandrostane- 3- one (DMAA)IBA 11/2021
1	16-fluoroestradiolIBA 08/2021
1	Volatile Fatty AcidsIBA 07/2021
1	Immune Checkpoint InhibitorsIBA 05/2021
1	Indicators and Reagents (Reagents)IBA 05/2021
1	Granzymes (Granzyme)IBA 05/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	Adenosine Triphosphate (ATP)IBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2020
1	OsteopontinIBA 02/2020
1	Docetaxel (Taxotere)FDA Link 02/2020
1	taxaneIBA 02/2020
1	Taxoids (Taxanes)IBA 02/2020
1	LipopolysaccharidesIBA 01/2020
1	hexanoic acid (hexanoate)IBA 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Cyclin DIBA 10/2019
1	Epidermal Growth Factor (EGF)IBA 10/2019
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2019
1	3,3',4',5-tetrachlorosalicylanilideIBA 01/2019
1	neratinibIBA 10/2018
1	HematinicsIBA 04/2018
1	Androgen Receptors (Androgen Receptor)IBA 01/2016
1	Estradiol Receptors (Estradiol Receptor)IBA 01/2016
1	Estrogen ReceptorsIBA 01/2016
1	AndrogensIBA 01/2016
1	Therapeutic UsesIBA 01/2016
1	Capecitabine (Xeloda)FDA Link 01/2016

Therapy/Procedure

17	Therapeutics 08/2021 - 01/2002
4	Drug Therapy (Chemotherapy) 02/2020 - 01/2012
2	Fundoplication 03/2016 - 12/2009
2	Nephrectomy 05/2010 - 11/2006
1	Anesthesia 01/2022
1	Osteotomy 11/2021
1	Castration 01/2016